Related Experiment Video

Updated: Jul 9, 2026

Tractable In Vivo Reprogramming of Tumor Cells to Type 1 Conventional Dendritic Cell-like Cells
10:04

Tractable In Vivo Reprogramming of Tumor Cells to Type 1 Conventional Dendritic Cell-like Cells

Published on: August 1, 2025

Dendritic cells in cancer immunotherapy

Annelie Vulink1, Kristen J Radford, Cornelis Melief

  • 1Mater Medical Research Institute, South Brisbane, QLD 4101, Australia.

Advances in Cancer Research
|November 27, 2007
PubMed

Insights

Dendritic cell (DC) cancer vaccines show promise but have yielded modest results. Future success may involve using activated DCs with multiple antigens in early-stage cancer patients and modulating immune tolerance.

Area of Science:

  • Immunology
  • Oncology
  • Vaccinology

Background:

  • Dendritic cells (DCs) are crucial for initiating immune responses against pathogens and cancers.
  • Clinical applications of DC-based cancer vaccines have shown limited efficacy to date.
  • Factors contributing to suboptimal outcomes include poor DC preparation, limited antigen selection, and trials in advanced-stage patients.

Purpose of the Study:

  • To review the progress in dendritic cell biology and cancer vaccine development.
  • To identify key factors limiting the efficacy of current DC cancer vaccines.
  • To propose strategies for improving the success of future DC-based cancer immunotherapies.

Main Methods:

  • Literature review of dendritic cell biology and cancer vaccine research.
  • Analysis of factors influencing the clinical outcomes of DC cancer vaccines.
  • Synthesis of data to propose future research directions and therapeutic strategies.

Main Results:

  • Significant advancements have been made in understanding DC biology.
  • Current DC cancer vaccines face challenges including suboptimal DC activation, limited tumor antigen specificity, and administration in late-stage disease.
  • Early intervention in minimal residual disease and modulation of immune tolerance are critical.

Conclusions:

  • Optimizing DC vaccine preparation and antigen loading is essential.
  • Administering vaccines to patients with minimal residual disease may improve outcomes.
  • Targeting regulatory mechanisms of peripheral tolerance holds potential for enhancing anti-cancer immunity.

More Related Videos

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine09:15

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

Preparation of Tumor Antigen-loaded Mature Dendritic Cells for Immunotherapy08:40

Preparation of Tumor Antigen-loaded Mature Dendritic Cells for Immunotherapy

Published on: August 1, 2013

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Cancer Vaccines01:30

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Cancer Stem Cells and Tumor Maintenance02:40

Cancer Stem Cells and Tumor Maintenance

Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
Cytotoxic T Cells-mediated Immune Response01:27

Cytotoxic T Cells-mediated Immune Response

Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
The Tumor Microenvironment02:17

The Tumor Microenvironment

Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...